Aura Biosciences, Inc. (NASDAQ:AURA) Stake Raised by Regency Capital Management Inc. DE

→ $5,000 Gold? (From Stansberry Research) (Ad)

Regency Capital Management Inc. DE boosted its stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 33.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 704,974 shares of the company's stock after buying an additional 177,996 shares during the quarter. Aura Biosciences makes up about 4.0% of Regency Capital Management Inc. DE's holdings, making the stock its 8th biggest position. Regency Capital Management Inc. DE owned about 1.84% of Aura Biosciences worth $6,246,000 as of its most recent filing with the SEC.

Get Aura Biosciences alerts:

A number of other institutional investors and hedge funds have also recently bought and sold shares of AURA. Royal Bank of Canada lifted its stake in shares of Aura Biosciences by 192.2% during the 2nd quarter. Royal Bank of Canada now owns 3,866 shares of the company's stock worth $47,000 after purchasing an additional 2,543 shares during the period. Tower Research Capital LLC TRC grew its holdings in Aura Biosciences by 257.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,604 shares of the company's stock valued at $59,000 after buying an additional 4,758 shares during the period. California State Teachers Retirement System grew its holdings in Aura Biosciences by 20.2% in the 1st quarter. California State Teachers Retirement System now owns 8,794 shares of the company's stock valued at $82,000 after buying an additional 1,478 shares during the period. Trexquant Investment LP purchased a new stake in Aura Biosciences in the 3rd quarter valued at about $95,000. Finally, Susquehanna International Group LLP purchased a new stake in Aura Biosciences in the 1st quarter valued at about $96,000. Hedge funds and other institutional investors own 96.75% of the company's stock.

Insider Buying and Selling

Ad Stansberry Research

Urgent dollar warning

Your 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.

Find out for free here.

In related news, CFO Julie B. Feder sold 6,609 shares of the business's stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $7.64, for a total transaction of $50,492.76. Following the transaction, the chief financial officer now directly owns 62,991 shares of the company's stock, valued at approximately $481,251.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,853 shares of the company's stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $7.64, for a total value of $121,116.92. Following the transaction, the insider now directly owns 161,438 shares of the company's stock, valued at approximately $1,233,386.32. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Julie B. Feder sold 6,609 shares of the company's stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $7.64, for a total value of $50,492.76. Following the completion of the transaction, the chief financial officer now directly owns 62,991 shares in the company, valued at $481,251.24. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, BTIG Research lowered their price target on Aura Biosciences from $38.00 to $21.00 and set a "buy" rating for the company in a report on Friday, December 8th.

Check Out Our Latest Research Report on Aura Biosciences

Aura Biosciences Price Performance

Aura Biosciences stock traded down $0.10 during midday trading on Wednesday, hitting $7.30. 95,530 shares of the company were exchanged, compared to its average volume of 181,877. The company's fifty day moving average price is $8.22 and its 200-day moving average price is $8.43. The company has a market cap of $279.30 million, a PE ratio of -3.80 and a beta of 0.36. Aura Biosciences, Inc. has a fifty-two week low of $5.99 and a fifty-two week high of $13.50.

Aura Biosciences Company Profile

(Free Report)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial.

Should you invest $1,000 in Aura Biosciences right now?

Before you consider Aura Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.

While Aura Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here